Qinghe Liang

Guangdong Provincial Key Laboratory Of New Drug Screening & Guangdong Hong Kong Macao Joint Laboratory For New Drug Screening
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2.

Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2.

Journal: International immunopharmacology

Published: March 09, 2026

Hexahydrocurcumin inhibits osteoclastogenesis and bone destruction in osteoporosis by targeting c-Src.

Hexahydrocurcumin inhibits osteoclastogenesis and bone destruction in osteoporosis by targeting c-Src.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 01, 2025

A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapy.

A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapy.

Journal: Biochemical pharmacology

Published: October 25, 2025

Corrigendum to "Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction" Adv. Res. 69 (2025) 399-411].

Corrigendum to "Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction" Adv. Res. 69 (2025) 399-411].

Journal: Journal of advanced research

Published: October 09, 2025

An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis.

An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis.

Journal: Biochemical pharmacology

Published: September 02, 2025

Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases.

Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases.

Journal: Pharmacological research

Published: January 23, 2025

Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction.

Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction.

Journal: Journal of advanced research

Published: January 13, 2024

Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.

Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: January 09, 2024

Immune-Cell-Based Therapy for COVID-19: Current Status.

Immune-Cell-Based Therapy for COVID-19: Current Status.

Journal: Viruses

Published: August 19, 2023

Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathway.

Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathway.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: June 15, 2023

Flot2 deficiency facilitates B cell-mediated inflammatory responses and endotoxic shock.

Flot2 deficiency facilitates B cell-mediated inflammatory responses and endotoxic shock.

Journal: Immunology

Published: March 21, 2023

Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling.

Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling.

Journal: International immunopharmacology

Published: February 22, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026